Mon, Dec 29, 2014
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Alternative Market Briefing

Return to operational profitability for Gottex in 2011

Tuesday, March 27, 2012

Beverly Chandler, Opalesque London: Results released by Gottex Fund Management Holdings Limited (Gottex), for the year ended 31 December 2011 show that the firm returned to operational profitability in 2011 with an operating profit of $0.7m. Gottex’s total fee-earning assets as at 31 December 2011 were $7.34bn, down 11% from $8.26bn at 31 December 2010. The total consists of $5.60bn in GFM assets under management and LUMAGSS assets of $1.74bn.

The firm highlighted:

  • Continued positive product performance during the first two months of 2012 with our core market neutral, multi-asset, alternative credit and Constellar multi-strat products up between 2% to 3%.
  • Gottex’s flagship market neutral plus product as well as the alternative credit strategy nearing their high water marks at the end of February 2012 and are close to accruing performance fees during Q2 2012.
  • LUMA-GSS assets of $1.85bn at the end of February 2012, up from $1.74bn at 31 December 2011.
  • Financial performance in-line with current expectations: gross revenues of $58.6m (2010: $63.8m) and substantially reduced overall operational cost of $48.2m (2010: $58.1m) resulted in an operating profit of $0.7m (2010: $5.0m loss); diluted EPS losses of $-0.09 (2010: $-0.10) was generated due to the impact of financial investments and certain impairment charges.
  • Cash and liquid financial investments of $50.8m.

Commenting, Joachim Gott......................

To view our full article Click here

Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing


  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Hong Kong-Shanghai stock link fails to live up to expectation so far[more]

    Komfie Manalo, Opalesque Asia: In a report, Reuters said that demand has been subdued with the bulk of activities coming from short-term speculative investors. Las

  2. Investing - Hedge funds get boost from healthcare in 2014, Paulson & Co takes stake in Salix on heels of inventory issues[more]

    Hedge funds get boost from healthcare in 2014 From Valuewalk.com: The healthcare sector started the year on a turbulent note, as stocks of many major biotechnology companies were battered. However, most of the players in this sector have bounced back. The BarclayHedge Healthcare & Biotec

  3. North America - Why Steve Cohen, Connecticut hedge fund billionaire, gives so much in New York[more]

    From Insidephilantrophy.com: Billionaire Steve Cohen was born in Great Neck, New York before attending Wharton, working on Wall Street and then founding SAC Capital Advisors in Connecticut. Though his company (Point72) and foundation are based in Connecticut, Cohen and Alexandra are deeply connected

  4. Investing - Soros buys a highly speculative biotech in the third quarter[more]

    From Fool.com: …The Soros Fund bought 25,000 shares of the struggling small-cap biopharma Aegerion Pharmaceuticals in the third quarter. For those of you who haven't heard of this name, suffice to say that this was a surprising buy in light of the company's recent problems and poor outlook going for

  5. CFTC Revokes Registrations of Illinois Resident Aleks A. Kins and Chicago-based AlphaMetrix, LLC[more]

    Matthias Knab, Opalesque: The U.S. Commodity Futures Trading Commission (CFTC) today announced that it has revoked the registration of Aleks A. Kins of Chicago, Illinois, as an Associated Person and the registrations of AlphaMetrix, LLC (AlphaMetrix), a Delaware limited liability company with its